Health DNA Tests UK (2026): BRCA, Pharmacogenomics, Predisposition Tests Compared
An honest UK guide to consumer and clinical-grade health DNA testing — what is genuinely useful, what is wellness theatre, when to use the NHS, and what private routes actually deliver value. Updated 11 June 2026.
The short version
- Use the NHS if you have strong family history of breast/ovarian/bowel cancer, suspected inherited cardiac conditions, or rare disease. Ask your GP for a Clinical Genetics referral. It is free and clinically validated.
- Consumer kits (£79–£199, 23andMe-style) are a starting point — good for ancestry and a few selected variants, but they miss thousands of clinically important mutations.
- Mid-tier predisposition panels (£150–£400) cover 10–50 conditions and are useful for curiosity-led pre-symptomatic screening — choose UKAS-accredited labs.
- Clinical-grade tests (£300–£2,500) — BRCA1/BRCA2, whole exome, whole genome — are the right choice if a result will trigger a real medical decision. Pair with genetic counselling.
- Pharmacogenomic (PGx) tests (£150–£350) can be genuinely useful before starting antidepressants, anticoagulants, or chemotherapy — discuss with your GP.
- Be sceptical of MTHFR-only tests, polygenic "longevity" scores, and ancestry-driven "diet DNA" reports. Most are not clinically validated.
What "health DNA testing" actually means
"Health DNA test" is an umbrella term covering very different products at very different price and accuracy points. Understanding the tiers before you spend money saves disappointment.
1. Consumer chip-based tests (£79–£199)
23andMe, AncestryDNA-Health, MyHeritage Health. These use SNP genotyping chips that read a fixed set of 600,000–700,000 single-letter DNA positions. Brilliant for ancestry. Reasonable for a small number of high-confidence variants (the FDA-cleared 23andMe BRCA report covers three specific Ashkenazi founder variants only). Poor for comprehensive health screening because chips do not read most of the genome.
2. Mid-tier predisposition panels (£150–£400)
Examples: easyDNA Health DNA, Living DNA Wellbeing, Atlas Biomed (limited UK availability). Typically 10–50 conditions, often a mix of monogenic risk markers and polygenic scores. Quality varies. Look for UKAS accreditation and ISO 15189-certified labs.
3. Pharmacogenomic (PGx) panels (£150–£350)
Examples: easyDNA Pharmacogenomic, several specialist labs via private GPs. Reads genes that affect drug metabolism — CYP2D6, CYP2C19, CYP2C9, VKORC1, DPYD, TPMT. Most useful before starting antidepressants, anticoagulants (warfarin), pain medication (codeine), or certain chemotherapy regimens.
4. Clinical-grade single-condition panels (£300–£700)
BRCA1/BRCA2, Lynch syndrome (MLH1/MSH2/MSH6), familial hypercholesterolaemia (LDLR/APOB/PCSK9), inherited cardiomyopathy panels. These are sequencing-based, read the relevant genes thoroughly, and are clinically actionable. The right tool if you have family history or a specific concern.
5. Whole exome / whole genome sequencing (£600–£2,500)
Reads either all 20,000 protein-coding genes (exome) or the entire genome including regulatory and non-coding regions. The most comprehensive option. Requires expert interpretation — raw data alone is overwhelming. Typically delivered with clinical geneticist review.
6. Raw-data upload services (£0–£70)
Promethease, GENOmapp, Sequencing.com. Take your 23andMe / AncestryDNA / MyHeritage raw file and run it against published variant databases. Useful for curiosity, dangerous if treated as medical advice. Most associations surfaced are research-grade, not clinical.
BRCA1 / BRCA2: when to test and how
Pathogenic variants in BRCA1 and BRCA2 substantially raise lifetime risk of breast and ovarian cancer (and increase risk of prostate, pancreatic and male breast cancer). Roughly 1 in 400 people in the general UK population carries a pathogenic variant; up to 1 in 40 in Ashkenazi Jewish ancestry.
Who should consider testing
- Multiple close relatives with breast or ovarian cancer, especially before age 50
- A relative with a confirmed BRCA variant
- Personal history of triple-negative breast cancer under 60
- Male breast cancer in the family
- Ashkenazi Jewish ancestry with any first-degree relative affected
NHS vs private routes
The NHS Genomic Medicine Service offers BRCA testing free for people meeting clinical eligibility criteria, with genetic counselling included. Waits are typically 2–4 months in 2026 depending on region. If you do not meet criteria but want testing, private clinical labs (Genesis Genetics, TDL Genetics, Cambridge BioMedica, Bupa) offer comprehensive BRCA panels for £350–£700, usually with optional counselling.
Avoid using 23andMe alone for serious BRCA decisions — the FDA-cleared 23andMe report screens only three Ashkenazi founder variants and misses the vast majority of pathogenic mutations. A negative 23andMe BRCA result does not mean BRCA-clear.
Pharmacogenomics (PGx): the most useful health DNA test most people have never heard of
PGx testing identifies how your genes affect drug metabolism. The clinical value is real and well-evidenced for specific drugs:
- CYP2D6, CYP2C19 — antidepressants (SSRIs, tricyclics), opioids (codeine, tramadol), beta-blockers, tamoxifen
- CYP2C9, VKORC1 — warfarin dosing
- DPYD — fluorouracil chemotherapy (the NHS now tests for this routinely)
- TPMT — azathioprine, 6-mercaptopurine (also NHS-tested before treatment)
- HLA-B*5701 — abacavir (HIV medication)
If you have struggled with antidepressant side-effects, are about to start a long-term medication, or have had unexpected drug reactions, a PGx panel can genuinely change prescribing. Bring the report to your GP or NHS pharmacist — many will engage with it, especially for the well-evidenced gene-drug pairs.
Private PGx panels in the UK: £150–£350. Some private GPs offer it as part of an integrated medicine review.
MTHFR, COMT, APOE: the wellness-industry darlings
MTHFR
The MTHFR gene encodes methylenetetrahydrofolate reductase, involved in folate metabolism. Variants C677T and A1298C are common — around 40% of UK adults carry at least one C677T copy. The mainstream genetics consensus from bodies like the American College of Medical Genetics is that routine MTHFR testing is not recommended for the general adult population. The wellness industry sells expensive methylated B vitamins on the back of these results; the evidence base does not support it for most people.
COMT
COMT variants affect dopamine metabolism. Some popular wellness narratives link COMT status to stress sensitivity, caffeine tolerance, even creativity. The evidence is weak and contradictory. Treat COMT-driven recommendations with strong scepticism.
APOE
APOE genotype is the strongest known genetic risk factor for late-onset Alzheimer\u2019s. APOE \u03b54 carriers face elevated lifetime risk; APOE \u03b54/\u03b54 homozygotes (around 2% of the population) face substantially higher risk. This is real signal — but most clinical bodies do not recommend routine APOE testing in healthy adults because:
- There is no proven preventive treatment
- Many \u03b54 carriers never develop Alzheimer\u2019s
- Many non-carriers do develop it
- The result can cause significant psychological distress
- It may complicate insurance applications (UK insurers cannot currently ask, but the policy is reviewed periodically)
If you decide to test, pair the result with genetic counselling. Consider why you want to know and what you would do differently.
Carrier screening before pregnancy
Carrier screening looks for recessive disease variants you might pass to a child if your partner is also a carrier. Common targets: cystic fibrosis, spinal muscular atrophy, fragile X, sickle cell, Tay-Sachs, beta-thalassaemia. Expanded panels cover 200–500 conditions.
The NHS offers limited targeted screening (sickle cell and thalassaemia universally in pregnancy; cystic fibrosis selectively). Private expanded carrier screening: £250–£700 per person. Worth considering pre-conception if either partner has known family history or comes from an ancestry group with elevated carrier rates for specific conditions.
See our NIPT prenatal genetic test guide for tests done during pregnancy.
How to choose a UK provider
Non-negotiable
- UKAS-accredited or ISO 15189-certified lab (check the website footer or ask)
- Clear statement of which variants are tested and which are not
- GDPR-compliant data handling, UK or EU data residency
- Stated policy on data sharing with third parties and research partners
Strong signals
- Optional genetic counselling available (essential for clinical-grade tests)
- Sample-collection method that suits you (saliva for most, blood for clinical-grade)
- Turnaround time stated upfront (usually 3–6 weeks)
- UK-based customer support
Red flags
- Marketing built around "epigenetic age", "DNA-personalised diet", or "ancestry-tailored supplements" without published validation
- No mention of the lab performing the analysis
- Vague pricing or auto-renewing subscriptions
- Claims to predict success in sport, intelligence, or romantic compatibility — none are clinically validated
NHS Genomic Medicine Service: how to access
The NHS Genomic Medicine Service (GMS) provides clinically indicated testing through seven regional Genomic Laboratory Hubs in England (similar structures in Scotland, Wales, NI). Routes in:
- GP referral to Clinical Genetics — for family history of cancer, inherited cardiac conditions, suspected rare disease
- Hospital-initiated testing — when a clinician suspects a genetic cause for current symptoms
- Pre-treatment PGx — DPYD before fluorouracil chemotherapy, TPMT before azathioprine, HLA-B*5701 before abacavir
- Antenatal carrier screening — universal for sickle cell and thalassaemia, selective for cystic fibrosis
If you suspect you would qualify, ask your GP for a referral. There is no cost. Genetic counselling is included. Waits vary by region — usually 2–4 months for non-urgent referrals in 2026.
Cost comparison table
| Test type | UK price range | What you get |
|---|---|---|
| Consumer chip (ancestry + health) | £79–£199 | Ancestry, selected variants, no counselling |
| Mid-tier predisposition panel | £150–£400 | 10–50 conditions, mixed quality, sometimes counselling |
| Pharmacogenomic panel | £150–£350 | Drug metabolism gene report, pharmacist or GP review optional |
| BRCA1/BRCA2 clinical panel | £300–£700 | Comprehensive sequencing, counselling usually included |
| Hereditary cancer multigene panel | £500–£1,200 | BRCA + Lynch + others, counselling included |
| Whole exome sequencing | £600–£1,500 | All protein-coding genes, expert interpretation required |
| Whole genome sequencing | £900–£2,500 | Entire genome, full interpretation pipeline |
| Expanded carrier screening | £250–£700 / person | 200–500 recessive conditions, pre-pregnancy planning |
| Raw-data upload analysis | £0–£70 | Curiosity-grade reports from existing 23andMe / Ancestry data |
What I would actually do
If I were spending my own money in 2026, in priority order:
- NHS Clinical Genetics referral if family history meets criteria — free, gold-standard, includes counselling
- Pharmacogenomic panel (£150–£350) if I have struggled with antidepressant side-effects or am about to start a long-term medication
- BRCA / hereditary cancer panel from a clinical-grade UK lab (£350–£1,200) if family history is suggestive but I do not meet NHS criteria
- Consumer ancestry kit (£79–£99) for fun and family history, treating any health information as preliminary only
What I would not spend money on: MTHFR-only tests, polygenic "longevity" scores, ancestry-tailored supplement subscriptions, or DNA-driven diet plans. Evidence is weak; the wellness industry is louder than the science.
Frequently asked questions
Are private health DNA tests accurate in the UK?
The raw DNA reading from a UKAS-accredited lab is highly reliable. The interpretation of what your variants mean for disease risk varies enormously. Single-gene findings like BRCA1/BRCA2 pathogenic variants are clinically meaningful; polygenic risk scores for things like "longevity" or "diet response" are largely unvalidated.
Can a private DNA test diagnose cancer risk like BRCA?
A clinically validated BRCA1/BRCA2 test can identify pathogenic variants linked to hereditary breast and ovarian cancer. Consumer kits (23andMe-style) screen only three specific Ashkenazi Jewish founder variants and miss thousands of other pathogenic mutations. For real BRCA screening, use the NHS Clinical Genetics route or a UKAS-accredited private clinical lab.
What is pharmacogenomic (PGx) testing?
PGx testing looks at genes affecting drug metabolism — CYP2D6, CYP2C19, CYP2C9, VKORC1, DPYD, TPMT. It can be genuinely useful before starting antidepressants, anticoagulants, or chemotherapy. The NHS already uses it selectively. Private panels: £150–£350. Most valuable when discussed with your GP or pharmacist.
Should I trust MTHFR results?
MTHFR variants are common (around 40% carry one C677T copy). The American College of Medical Genetics, the NHS, and mainstream UK clinical bodies do not recommend routine MTHFR testing for healthy adults. Treat wellness-industry MTHFR claims with strong scepticism.
NHS vs private — when does the NHS cover health DNA testing?
NHS Genomic Medicine Service covers clinically indicated testing: strong family history of breast/ovarian/bowel cancer, suspected inherited cardiac conditions, suspected rare disease, pre-treatment PGx, antenatal carrier screening. Ask your GP for a Clinical Genetics referral if family history is concerning.
How much does a health DNA test cost in the UK?
Consumer combo kits £79–£199. Mid-tier predisposition panels £150–£400. Clinical-grade BRCA panel £300–£700. Whole exome £600–£1,500. Whole genome £900–£2,500. Pharmacogenomic panels £150–£350. Carrier screening £250–£700.
Are 23andMe results reliable for health?
Excellent for ancestry and a small number of high-confidence variants. Limited for comprehensive health screening — chip-based testing misses thousands of clinically important mutations that only sequencing catches. A starting point, not a clinical answer.
Can I upload raw DNA data for health analysis?
Yes — Promethease, GENOmapp, Sequencing.com accept raw uploads from 23andMe, AncestryDNA, MyHeritage, Living DNA. Reports cost £0–£70. Useful for curiosity; not a substitute for clinical genetics review.
What about APOE testing for Alzheimer\u2019s?
APOE \u03b54 is the strongest known genetic risk factor for late-onset Alzheimer\u2019s. Risk, not destiny. Most clinical bodies do not recommend routine APOE testing in healthy adults because there is no preventive treatment and the result can cause significant distress. Think hard before opting in.
Is genetic counselling included?
Rarely with consumer kits. Sometimes with mid-tier panels (optional add-on). Almost always with clinical-grade BRCA or hereditary cancer panels from regulated providers. If the result might trigger a major decision, pay for the counselling — or get an NHS Clinical Genetics referral after the result lands.